KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.63B
- P/E (TTM)
- 81.9
- Dividend yield
- –
Kiniksa Pharmaceuticals International, plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $840.85M | $754.05M | $677.56M | $597.97M | $529.33M | $475.93M | $417.03M | $365.71M | $318.30M | $269.40M | $233.18M | $201.90M | 100.0% | +58.9% |
| License and collaboration revenue | – | – | – | – | – | – | $6.21M | $18.39M | $20.63M | $32.37M | $37.08M | $46.85M | – | – |
By region
From the segment and revenue-disaggregation notes of Kiniksa Pharmaceuticals International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.